|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
Pfizer Inc. (NYSE:PFE) ranks among the top picks for a retirement portfolio. BMO Capital reaffirmed its Outperform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on September 23 in response to the company’s announcement of a new agreement in the obesity treatment market.
Following disappointments with its lotiglipron and danuglipron programs, the pharmaceutical giant has now made what BMO Capital refers to as a “thoughtful re-entry into the obesity metabolic space” with its partnership with Metsera.
With contingent value rights (CVRs) built into the deal, BMO Capital considers it as “one of Pfizer’s better BD opportunities,” allowing the company to lower risk and regain its competitive position in the market for obesity treatments.
Pfizer Inc. (NYSE:PFE) is a leading global pharmaceutical company that develops, produces, and sells biopharmaceutical medicines worldwide.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This article is originally published at Insider Monkey.
| 4 hours | |
| 4 hours | |
| 6 hours | |
| 10 hours | |
| 10 hours | |
| 12 hours | |
| 13 hours | |
| 14 hours | |
| 15 hours | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite